Identification of a Tumor-Promoter Cholesterol Metabolite in Human Breast Cancers Acting Through the Glucocorticoid Receptor

Total Page:16

File Type:pdf, Size:1020Kb

Identification of a Tumor-Promoter Cholesterol Metabolite in Human Breast Cancers Acting Through the Glucocorticoid Receptor Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor Maud Voisina,b,1, Philippe de Medinac,1, Arnaud Mallingera,b,1, Florence Dalenca,b,d, Emilie Huc-Claustrea,b, Julie Leignadiera,b, Nizar Serhana,b, Régis Soulesa,b, Grégory Ségalaa,b, Aurélie Mougela,b, Emmanuel Noguera,b,c, Loubna Mhamdic, Elodie Bacquiéa,b, Luigi Iulianoe, Chiara Zerbinatie, Magali Lacroix-Trikid, Léonor Chaltield, Thomas Fillerond, Vincent Cavaillèsf, Talal Al Saatig, Philippe Rochaixd, Raphaelle Duprez-Paumierd, Camille Franchetd, Laetitia Ligath, Fréderic Lopezh, Michel Recorda,b, Marc Poirota,b,2, and Sandrine Silvente-Poirota,b,2 aTeam “Cholesterol Metabolism and Therapeutic Innovations,” Cancer Research Center of Toulouse (CRCT), UMR 1037, Université de Toulouse, CNRS, Inserm, UPS, 31037 Toulouse, France; bUniversité Paul Sabatier, 31062 Toulouse, France; cAffichem, 31400 Toulouse, France; dInstitut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, 31059 Toulouse, France; eVascular Biology, Atherothrombosis & Mass Spectrometry Laboratory, Sapienza University of Rome, 04100 Latina, Italy; fl’Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, University of Montpellier, F-34298 Montpellier, France; gINSERM/UPS-US006/Centre Régional d’Exploration Fonctionnelle et Ressources Expérimentales, Service d’Histopathologie, Centre Hospitalier Universitaire Purpan, 31024 Toulouse, France; and hPôle Technologique, Cancer Research Center of Toulouse (CRCT), Plateau Interactions Moléculaires, INSERM-UMR1037, 31037 Toulouse, France Edited by Christopher K. Glass, University of California, San Diego, La Jolla, CA, and approved September 15, 2017 (received for review May 13, 2017) Breast cancer (BC) remains the primary cause of death from cancer ER, Tam also impacts on cholesterol metabolism by targeting among women worldwide. Cholesterol-5,6-epoxide (5,6-EC) metab- cholesterol epoxide hydrolase (ChEH), an enzymatic complex olism is deregulated in BC but the molecular origin of this is formed by two cholesterogenic enzymes, DHCR7 and D8D7I unknown. Here, we have identified an oncometabolism downstream (also known as EBP) (5–7). In normal tissues, ChEH catalyzes of 5,6-EC that promotes BC progression independently of estrogen the hydrolysis of the cholesterol 5,6-epoxides α and β (5,6α-EC receptor α expression. We show that cholesterol epoxide hydrolase and 5,6β-EC) into cholestane-3β,5α,6β-triol (CT) (5, 6, 8). In β α β (ChEH) metabolizes 5,6-EC into cholestane-3 ,5 ,6 -triol, which is normal mammalian tissues, 5,6α-EC reacts with histamine via an β α transformed into the oncometabolite 6-oxo-cholestan-3 ,5 -diol enzyme to produce a tumor suppressor metabolite named den- (OCDO) by 11β-hydroxysteroid-dehydrogenase-type-2 (11βHSD2). β drogenin A (DDA), whose levels are significantly decreased in 11 HSD2 is known to regulate glucocorticoid metabolism by convert- BC compared with normal adjacent tissues (NAT), indicating a ing active cortisol into inactive cortisone. ChEH inhibition and deregulation of this pathway during BC development (3, 4). 11βHSD2 silencing inhibited OCDO production and tumor growth. These data combined suggest a potential role of ChEH activa- Patient BC samples showed significant increased OCDO levels and greater ChEH and 11βHSD2 protein expression compared with nor- tion in BC progression that we explored in the present study. mal tissues. The analysis of several human BC mRNA databases in- Herein, we describe how this led us to discover an oncometabolite, dicated that 11βHSD2 and ChEH overexpression correlated with a higher risk of patient death, highlighting that the biosynthetic path- Significance way producing OCDO is of major importance to BC pathology. OCDO stimulates BC cell growth by binding to the glucocorticoid receptor Cholesterol and its transformation into cholesterol-5,6-epoxides (GR), the nuclear receptor of endogenous cortisol. Interestingly, high (5,6-EC) was long suspected as contributing to breast cancer (BC) GR expression or activation correlates with poor therapeutic re- pathogenesis, before it was found that 5,6-EC metabolism con- sponse or prognosis in many solid tumors, including BC. Targeting trols BC development and is deregulated in breast cancers. the enzymes involved in cholesterol epoxide and glucocorticoid me- Herein, we studied in tumor cells and human samples how 5,6-EC tabolism or GR may be novel strategies to prevent and treat BC. metabolism deregulation promotes tumor progression. We have discovered a pathway in BCs producing an oncometabolite de- breast cancer | oncometabolism | dendrogenin A | therapy | rived from 5,6-EC, through the action of the cortisol-inactivating nuclear receptor enzyme, and identified the glucocorticoid receptor (GR) as the target mediating its proliferative effects. Inhibition of its pro- role for cholesterol in the etiology of cancers has long been duction or GR significantly blocked its action on BC progression. Asuspected, and 5,6-cholesterol epoxides (5,6-EC) were ini- Thus, targeting this oncometabolism and GR represents a new tially thought to be the causative agents. However, recent data opportunity for therapeutic intervention in BCs and potentially have now shown that it is the metabolism of 5,6-EC that is other cancers presenting such deregulations. deregulated in breast cancer (BC), and that this metabolism – Author contributions: M.P. and S.S.-P. designed research; M.V., P.d.M., A. Mallinger, F.D., controls BC development (1 4). To develop novel precision E.H.-C., J.L., N.S., R.S., G.S., A. Mougel, E.N., L.M., E.B., C.Z., M.L.-T., T.A.S., R.D.-P., C.F., L.L., M.R., therapeutic strategies, a deeper understanding of 5,6-EC me- M.P., and S.S.-P. performed research; M.V., P.d.M., A. Mallinger, F.D., E.H.-C., J.L., N.S., R.S., tabolism is required. Indeed, BC remains the most frequent G.S., A. Mougel, E.N., L.M., E.B., L.I., C.Z., M.L.-T., L.C., T.F., V.C., T.A.S., P.R., R.D.-P., C.F., L.L., F.L., M.R., M.P., and S.S.-P. analyzed data; and M.P. and S.S.-P. wrote the paper. cause of death from cancer among women worldwide, despite Conflict of interest statement: P.d.M., E.N., and L.M. are employees of the company the development of targeted therapies, such as Tamoxifen (Tam) Affichem, of which S.S.-P. and M.P. are founders. for treating tumors expressing the estrogen receptor (ER), or This article is a PNAS Direct Submission. agents that target the overexpressed growth factor receptor Published under the PNAS license. HER2 (human epidermal growth factor receptor). These failures 1M.V., P.d.M., and A. Mallinger contributed equally to this work. are explained by the fact that many BC do not respond to these 2To whom correspondence may be addressed. Email: [email protected] or sandrine. therapies or develop resistance, and there are currently no ef- [email protected]. fective targeted therapies to treat tumors that express neither ER This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. nor HER2. In addition to its role as a competitive inhibitor for 1073/pnas.1707965114/-/DCSupplemental. E9346–E9355 | PNAS | Published online October 12, 2017 www.pnas.org/cgi/doi/10.1073/pnas.1707965114 Downloaded by guest on September 29, 2021 6-oxo-cholestan-3β,5α-diol (OCDO), that drives BC progression were treated with 5,6α-EC for 72 h, then lipids were extracted PNAS PLUS through the glucocorticoid receptor (GR). Furthermore, we and submitted to RP-HPLC. Mass spectrometric analysis of the 9- to 11-min RP-HPLC fractions (Fig. 2D) showed peaks of m/z show that OCDO is derived from 5,6-ECs through the action + + of ChEH and the cortisol-inactivating enzyme, 11βHSD2. [M+NH4] = 438.6 and m/z [M+N2H7] = 455.6, corresponding Inhibiting this oncometabolic pathway or GR significantly re- to the mass of CT and consistent with the transformation of duced BC proliferation, suggesting that targeting the actors of 5,6α-EC into CT by ChEH (Fig. 2E). Analysis of the 15- to this pathway could represent new strategies in BC therapy and 17-min RP-HPLC fractions (Fig. 2D) showed peaks of m/z + + = m/z + + = F prevention. [MUM NH4] 436.6 and [MUM N2H7] 453.6 (Fig. 2 ), corresponding to the mass of sOCDO. This confirmed that the Results UM was OCDO (Fig. 2G). Kinetic Analysis of 5,6-EC and CT Metabolism in MCF7 Cells. We first examined the metabolism of [14C]5,6α-EC, [14C]5,6β-EC, and ChEH Inhibition Abrogates OCDO Formation in BC Cells. We next [14C]CT over a 72-h period in the breast cancer cell line MCF7. measured the impact of DDA and other ChEH inhibitors (3, 5) Thin-layer chromatography (TLC) analyses of cell and media on OCDO formation by incubating human MCF7 or MDA-MB- α extracts showed that 5,6α-EC (Fig. 1 A and B) and 5,6β-EC (Fig. 231 tumor cells (expressing or not the ER , respectively) with 14 α 1 C and D) were first converted into CT (retention factor, Rf = [ C]5,6 -EC and the indicated ChEH inhibitors. As shown in A B 0.21) as a result of ChEH activity. However, over time, an un- Fig. 3 and , in both cell lines DDA and the ChEH inhibitors known metabolite (UM), Rf = 0.60, appeared and its level in- tested inhibited OCDO production, including ChEH inhibitors creased at the expense of the 5,6-ECs and CT. Similar experiments known to have antitumor activity and to inhibit ERα, such as performed using [14C]CT alone revealed that the UM was a me- Tam or raloxifene, or to act independently of the ERα, such as tabolite of CT (Fig.
Recommended publications
  • Microsomal Antiestrogen-Binding Site Ligands Induce Growth Control and Differentiation of Human Breast Cancer Cells Through the Modulation of Cholesterol Metabolism
    3707 Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism Bruno Payre´,1,2,3,5 Philippe de Medina,1,4 with other AEBS ligands and with zymostenol and DHC. Nadia Boubekeur,1,2,3 Loubna Mhamdi,4 Vitamin E abrogates the induction of differentiation and Justine Bertrand-Michel,6 Franc¸ois Terce´,6 reverses the control of cell growth produced by AEBS Isabelle Fourquaux,3,5 Dominique Goudoune`che,3,5 ligands, zymostenol, and DHC, showing the importance Michel Record,1,2,3 Marc Poirot,1,2,3 of the oxidative processes in this effect. AEBS ligands induced differentiation in estrogen receptor-negative and Sandrine Silvente-Poirot1,2,3 mammary tumor cell lines SKBr-3 and MDA-MB-468 but 1INSERM, U-563; 2Institut Claudius Regaud; 3Universite´Toulouse with a lower efficiency than observed with MCF-7. Toge- III Paul Sabatier; 4Affichem; 5Universite´Toulouse III Paul Sabatier, ther, these data show that AEBS ligands exert an anti- Faculte´deMe´decine Toulouse-Rangueil, Centre de Microscopie proliferative effect on mammary cancer cells by inducing 6 Electronique Applique´e` a la Biologie; Plateau technique de cell differentiation and growth arrest and highlight the lipidomique, IFR30, Genopole Toulouse, INSERM U-563, Toulouse, France importance of cholesterol metabolism in these effects. [Mol Cancer Ther 2008;7(12):3707–18] Abstract Introduction The microsomal antiestrogen-binding site (AEBS) is a high- affinity membranous binding site for the antitumor drug The microsomal antiestrogen-binding site (AEBS) was first tamoxifen that selectively binds diphenylmethane deriva- described in the 1980s as a high-affinity binding site for tives of tamoxifen such as PBPE and mediates their anti- tamoxifen,distinct from the estrogen receptors (ER; ref.
    [Show full text]
  • WO 2013/152252 Al 10 October 2013 (10.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/152252 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: STEIN, David, M.; 1 Bioscience Park Drive, Farmingdale, Λ 61Κ 38/00 (2006.01) A61K 31/517 (2006.01) NY 11735 (US). MIGLARESE, Mark, R.; 1 Bioscience A61K 39/00 (2006.01) A61K 31/713 (2006.01) Park Drive, Farmingdale, NY 11735 (US). A61K 45/06 (2006.01) A61P 35/00 (2006.01) (74) Agents: STEWART, Alexander, A. et al; 1 Bioscience A61K 31/404 (2006 ) A61P 35/04 (2006.01) Park Drive, Farmingdale, NY 11735 (US). A61K 31/4985 (2006.01) A61K 31/53 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: available): AE, AG, AL, AM, PCT/US2013/035358 kind of national protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 5 April 2013 (05.04.2013) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, English (25) Filing Language: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (30) Priority Data: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/621,054 6 April 2012 (06.04.2012) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (71) Applicant: OSI PHARMACEUTICALS, LLC [US/US]; ZM, ZW.
    [Show full text]
  • Ligands of the Antiestrogen-Binding Site Induce Active Cell Death and Autophagy in Human Breast Cancer Cells Through the Modulation of Cholesterol Metabolism
    Cell Death and Differentiation (2009) 16, 1372–1384 & 2009 Macmillan Publishers Limited All rights reserved 1350-9047/09 $32.00 www.nature.com/cdd Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism P de Medina1,2,3,7, B Payre´ 1,2,4,5,7, N Boubekeur1,2,4, J Bertrand-Michel6, F Terce´6, S Silvente-Poirot1,2,4,8 and M Poirot*,1,2,4 We have recently reported that cytostatic concentrations of the microsomal antiestrogen-binding site (AEBS) ligands, such as PBPE (N-pyrrolidino-(phenylmethyphenoxy)-ethanamine,HCl) and tamoxifen, induced differentiation characteristics in breast cancer cells through the accumulation of post-lanosterol intermediates of cholesterol biosynthesis. We show here that exposure of MCF-7 (human breast adenocarcinoma cell line) cells to higher concentrations of AEBS ligands triggered active cell death and macroautophagy. Apoptosis was characterized by Annexin V binding, chromatin condensation, DNA laddering and disruption of the mitochondrial functions. We determined that cell death was sterol- and reactive oxygen species-dependent and was prevented by the antioxidant vitamin E. Macroautophagy was characterized by the accumulation of autophagic vacuoles, an increase in the expression of Beclin-1 and the stimulation of autophagic flux. We established that macroautophagy was sterol- and Beclin-1-dependent and was associated with cell survival rather than with cytotoxicity, as blockage of macroautophagy sensitized cells to AEBS ligands. These results show that the accumulation of sterols by AEBS ligands in MCF-7 cells induces apoptosis and macroautophagy. Collectively, these data support a therapeutic potential for selective AEBS ligands in breast cancer management and shows a mechanism that explains the induction of autophagy in MCF-7 cells by tamoxifen and other selective estrogen receptor modulators.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
    US 20090226431A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub. Date: Sep. 10, 2009 (54) TREATMENT OF CANCER AND OTHER Publication Classification DISEASES (51) Int. Cl. A 6LX 3/575 (2006.01) (76)76) InventorInventor: Nabilabil Habib,Habib. Beirut (LB(LB) C07J 9/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) 101 FEDERAL STREET A6IP 29/00 (2006.01) A6IP35/00 (2006.01) (21) Appl. No.: 12/085,892 A6IP37/00 (2006.01) 1-1. (52) U.S. Cl. ...................... 424/133.1:552/551; 514/182: (22) PCT Filed: Nov.30, 2006 514/171 (86). PCT No.: PCT/US2O06/045665 (57) ABSTRACT .."St. Mar. 6, 2009 The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3B.5C,6C.-triol), its production, its use, and to methods of treating neoplasms and other tumors as Related U.S. Application Data well as other diseases including hypercholesterolemia, (60) Provisional application No. 60/741,725, filed on Dec. autoimmune diseases, viral diseases (e.g., hepatitis B, hepa 2, 2005. titis C, or HIV), and diabetes. F2: . - 2 . : F2z "..., . Cz: ".. .. 2. , tie - . 2 2. , "Sphagoshgelin , , re Cls Phosphatidiglethanolamine * - 2 .- . t - r y ... CBs .. A . - . Patent Application Publication Sep. 10, 2009 Sheet 1 of 16 US 2009/0226431 A1 E. e'' . Phosphatidylcholine. " . Ez'.. C.2 . Phosphatidylserias. * . - A. z' C. w E. a...2 .". is 2 - - " - B 2. Sphingoshgelin . Cls Phosphatidglethanglamine Figure 1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 16 US 2009/0226431 A1 Chile Phosphater Glycerol Phosphatidylcholine E.
    [Show full text]
  • Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance in Vitro Using in Silico Identified Novel Compounds
    Southern Methodist University SMU Scholar Biological Sciences Theses and Dissertations Biological Sciences Spring 5-18-2019 Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance In Vitro Using In Silico Identified Novel Compounds Amila Nanayakkara Southern Methodist University, [email protected] Follow this and additional works at: https://scholar.smu.edu/hum_sci_biologicalsciences_etds Part of the Cancer Biology Commons, Cell Biology Commons, Other Chemicals and Drugs Commons, Pharmaceutical Preparations Commons, and the Pharmacology Commons Recommended Citation Nanayakkara, Amila, "Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance In Vitro Using In Silico Identified Novel Compounds" (2019). Biological Sciences Theses and Dissertations. 3. https://scholar.smu.edu/hum_sci_biologicalsciences_etds/3 This Dissertation is brought to you for free and open access by the Biological Sciences at SMU Scholar. It has been accepted for inclusion in Biological Sciences Theses and Dissertations by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu. REVERSAL OF P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN MEDIATED MULTIDRUG RESISTANCE IN VITRO USING IN SILICO IDENTIFIED NOVEL COMPOUNDS. Approved by, __________________________ Prof. John Wise Associate Professor of Biology __________________________ Prof. Pia Vogel Professor of Biology __________________________ Prof. Steven Vik Professor of Biology __________________________ Prof. Alex Lippert Associate Professor of Chemistry REVERSAL OF P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN MEDIATED MULTIDRUG RESISTANCE IN VITRO USING IN SILICO IDENTIFIED NOVEL COMPOUNDS A Dissertation Presented to the Graduate Faculty of Dedman College Southern Methodist University in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy with a Major in Molecular and Cell Biology by Amila K.
    [Show full text]
  • IGFBP2-Biomarker
    (19) & (11) EP 2 405 270 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.01.2012 Bulletin 2012/02 G01N 33/574 (2006.01) C07K 16/28 (2006.01) G01N 33/68 (2006.01) (21) Application number: 11162598.4 (22) Date of filing: 29.06.2007 (84) Designated Contracting States: (71) Applicant: Schering Corporation AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Kenilworth, NJ 07033 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: Wang, Yan Designated Extension States: Warren, NJ 07059 (US) AL BA HR MK RS (74) Representative: Vossius & Partner (30) Priority: 30.06.2006 US 818004 P Siebertstrasse 4 81675 München (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07810179.7 / 2 032 989 This application was filed on 15-04-2011 as a divisional application to the application mentioned under INID code 62. (54) IGFBP2-Biomarker (57) The present invention provides method for cally relevant determinations may be made based on this quickly and conveniently determining if a given treatment point, including, for example, whether the dosage of the regimen of IGF1R inhibitor is sufficient, e.g., to saturate regimen is sufficient or should be increased. IGF1R receptors in the body of a subject. Several clini- EP 2 405 270 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 405 270 A1 Description [0001] This application claims the benefit of U.S. provisional patent application no.
    [Show full text]
  • Pathophysiological Implications of Neurovascular P450 in Brain Disorders, Drug Discov Today (2016), J.Drudis.2016.06.004
    Drug Discovery Today Volume 00, Number 00 June 2016 REVIEWS The expression and function of P450 enzymes at the neurovascular unit have a key role in drug resistance and brain cell viability. KEYNOTE REVIEW Pathophysiological implications of neurovascular P450 in brain disorders Reviews 1,2,3 1,2 4 Chaitali Ghosh received Chaitali Ghosh , Mohammed Hossain , Jesal Solanki , her PhD in toxicology from 4 5 6 the Indian Institute of Aaron Dadas , Nicola Marchi and Damir Janigro Toxicology Research, Lucknow (India) and 1 Cerebrovascular Research, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA Hamdard University, New 2 Delhi (India) with Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA 3 subsequent postdoctoral Department of Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA 4 training in vascular biology The Ohio State University, Columbus, OH, USA 5 and epilepsy at the Cleveland Clinic (USA). She is Cerebrovascular Mechanisms of Brain Disorders, Department of Neuroscience, Institute of Functional Genomics currently an assistant professor in molecular medicine (CNRS/INSERM), Montpellier, France at the Cleveland Clinic Lerner College of Medicine 6 Flocel Inc. and Case Western Reserve University, Cleveland, OH, USA and Case Western Reserve University. She leads the Brain Physiology Laboratory in the Department of Biomedical Engineering, Cleveland Clinic Lerner Over the past decades, the significance of cytochrome P450 (CYP) enzymes Research Institute and her expertise lies in neurobiology, the blood–brain barrier, drug-resistant has expanded beyond their role as peripheral drug metabolizers in the liver epilepsy, neuropharmacology, and toxicology. and gut. CYP enzymes are also functionally active at the neurovascular interface.
    [Show full text]
  • Identification and Pharmacological Characterization of Cholesterol-5, 6-Epoxide Hydrolase As a Target for Tamoxifen and AEBS Ligands
    Correction PHARMACOLOGY Correction for “Identification and pharmacological character- Acad Sci USA (107:13520–13525; first published July 6, 2010; ization of cholesterol-5,6-epoxide hydrolase as a target for ta- 10.1073/pnas.1002922107). moxifen and AEBS ligands,” by Philippe de Medina, Michael R. The authors note that, due to a printer’s error, the online Paillasse, Gregory Segala, Marc Poirot, and Sandrine Silvente- version of Table 1 was formatted incorrectly. The table appears Poirot, which appeared in issue 30, July 27, 2010, of Proc Natl correctly in the print version and is shown below. Table 1. Inhibition of [3H]Tam binding to the AEBS and catalytic activity of ChEH by drugs Compound Ki AEBS, nM Ki ChEH, nM Selective AEBS ligands PBPE 1 9 ± 127± 6 PCPE 2 10 ± 135± 8 Tesmilifene 3 56 ± 262± 3 MBPE 4 18 ± 127± 6 MCPE 5 48 ± 257± 8 PCOPE 6 64 ± 4 203 ± 11 MCOPE 7 102 ± 16 241 ± 7 MCOCH2PE 8 850 ± 12 902 ± 13 SERMs Tamoxifen 9 2.5 ± 0.2 34 ± 8 4OH-Tamoxifen 10 11 ± 1 145 ± 4 Raloxifene 11 6 ± 136± 4 Nitromiphene 12 2.4 ± 0.3 18 ± 6 Clomiphene 13 1.5 ± 0.2 9 ± 2 RU 39,411 14 38 ± 1 155 ± 8 σ receptor ligands BD-1008 15 83 ± 199± 9 Haloperidol 16 5,322 ± 9 18,067 ± 14 SR-31747A 17 1.2 ± 0.1 6 ± 2 Ibogaine 18 920 ± 12 2,150 ± 11 AC-915 19 1,120 ± 8 3,527 ± 9 Rimcazole 20 640 ± 5 2,325 ± 8 Amiodarone 21 432 ± 22 733 ± 9 Trifluoroperazine 22 14 ± 2 135 ± 7 Cholesterol biosynthesis inhibitors Ro 48–8071 23 110 ± 489± 5 U-18666A 24 84 ± 290± 5 AY-9944 25 358 ± 12 649 ± 6 Triparanol 26 17 ± 239± 3 Terbinafine 27 3,720 ± 16 9,105 ± 33 SKF-525A
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Development and Clinical Application of Oral Dosage Forms of Taxanes
    Development and clinical application of oral dosage forms of taxanes ISBN/EAN: 978-90-820193-1-5 © Johannes Moes, Amsterdam/Goes Artwork: Bart Nijstad – www.bartnijstad.com Layout and design: Esther Ris – www.proefschriftomslag.nl Printed by: Gildeprint drukkerijen - www.gildeprint.nl Development and clinical application of oral dosage forms of taxanes Ontwikkeling en klinische toepassing van orale toedieningsvormen van taxanen (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op woensdag 30 oktober 2013 des middags te 2.30 uur door Johannes Jan Moes geboren op 8 december 1979 te Nijeveen Promotoren: Prof.dr. J.H. Beijnen Prof.dr. J.H.M Schellens Co-promotor: Dr. B. Nuijen The research described in this thesis was performed at the Department of Pharmacy & Pharmacology, Slotervaart Hospital / The Netherlands Cancer Institute, Amsterdam, The Netherlands & The Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands Printing of this thesis was financially supported by: Huisartsenpraktijk Kolderveen, Nijeveen, The Netherlands Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands The Netherlands Laboratory for Anticancer Drug Formulation (NLADF), Amsterdam, The Netherlands TEVA Pharmachemie BV, Haarlem, The Netherlands Boehringer Ingelheim BV, Alkmaar, The Netherlands Table of contents 1. Introduction 2. Oral formulations of docetaxel and paclitaxel - a mini review 3. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001) 4. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel 5.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0022235 A1
    US 20190022235A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0022235 A1 Durfee et al. (43 ) Pub . Date : Jan . 24 , 2019 ( 54 ) OSTEOTROPIC NANOPARTICLES FOR Publication Classification PREVENTION OR TREATMENT OF BONE (51 ) Int. Cl. METASTASES A61K 47 /54 (2006 .01 ) A61K 47 /69 (2006 . 01) ( 71 ) Applicants : Paul N . Durfee, Albuquerque , NM A61K 47 / 10 ( 2006 .01 ) (US ) ; Charles Jeffrey Brinker , A61K 9 / 16 (2006 . 01 ) Albuquerque , NM (US ); Yu - shen Lin , A61P 35 /00 (2006 .01 ) Seattle , WA ( US ) ; Hon Leong , London ( 52 ) U .S . CI. (CA ) CPC . .. A61K 47 /548 ( 2017 . 08 ) ; A61K 47 /6923 (72 ) Inventors: Paul N . Durfee , Albuquerque , NM ( 2017 . 08 ) ; B82Y 5 / 00 ( 2013 .01 ) ; A61K 9 / 16 (US ) ; Charles Jeffrey Brinker , ( 2013 .01 ) ; A61P 35 / 00 ( 2018 .01 ) ; A61K 47/ 10 Albuquerque, NM (US ) ; Yu - shen Lin , ( 2013. 01 ) Seattle , WA (US ) ; Hon Leong , London (57 ) ABSTRACT (CA ) The present disclosure is directed to protocells or nanopar ticles, which are optionally coated with a lipid bilayer, which (21 ) Appl. No. : 16 /068 , 235 can be used for targeting bone tissue for the delivery of bioactive agents useful in the treatment and /or diagnosis of ( 22 ) PCT Filed : Jan . 6 , 2017 bone cancer , often metastatic bone cancer which often occurs secondary to a primary cancer such as prostate ( 86 ) PCT No .: PCT/ US2017 /012583 cancer, breast cancer, lung cancer and ovarian cancer, among $ 371 ( C ) ( 1 ) , numerous others . These protocells or nanoparticles target ( 2 ) Date : Jul. 5 , 2018 bone cancer especially metastatic bone cancer with bioactive agents including anticancer agents and /or diagnostic agents for purposes of treating , diagnosing and / or monitoring the Related U .
    [Show full text]